Insurance Company Files Actos Bladder Cancer Lawsuit
June 21, 2014
Blue Cross and Blue Shield of Massachusetts (BCBSMA) has filed a lawsuit, on behalf of its insured members, against Takeda Pharmaceuticals, maker of the diabetes drug, Actos. The suit charges the Japanese company with hiding evidence that Actos causes bladder cancer and also names Takeda’s U.S. marketing partner, Eli Lilly and Company.
Actos Maker Intentionally Destroyed Evidence, Judge Rules
June 20, 2014
A federal judge in Louisiana has ruled that Takeda Pharmaceuticals intentionally destroyed evidence relevant to multidistrict litigation involving Takeda’s diabetes drug Actos. The ruling affects over 6,000 lawsuits that have been consolidated before U.S. District Judge Rebecca Doherty, who issued today’s ruling. Plaintiffs in those cases have charged Takeda with concealing evidence and failing to warn patients and health care providers that Actos significantly increases the risk of bladder cancer.
Las Vegas Judge Issues Sanctions Against Takeda Lawyers
May 1, 2014
A District Court judge has issued sanctions against lawyers for Takeda Pharmaceuticals in a trial currently underway in Las Vegas. In an order filed yesterday, the judge ruled that attorneys for Takeda violated pretrial evidentiary rulings nine times and “repeatedly engaged in disruptive and disrespectful behavior towards the court.” Plaintiffs in the case, Delores Cipriano, 81, of Henderson, NV, and Bertha Triana, 80, of Las Vegas, are both suffering from bladder cancer, which they claim was caused by Takeda’s diabetes drug, Actos. They are seeking a multibillion-dollar verdict against the Japanese drug maker.
Takeda, Lilly Jury Awards $9 Billion Over Actos Risks
Takeda Pharmaceutical Co. and Eli Lilly & Co. were ordered to pay a combined $9 billion in punitive damages after a federal court jury found they hid the cancer risks of their Actos diabetes medicine. This is the first United States trial of its kind.
April 8, 2014
Trial Starts for Two Nevada Women who Developed Bladder Cancer after taking Actos
March 10, 2014
A product liability case against Takeda Pharmaceuticals, the manufacturer of a diabetes drug called Actos (pioglitazone), is scheduled to begin on Monday in Las Vegas, Nevada. Clark County residents Delores Cipriano and Bertha Triana both claim to have developed bladder cancer as a result of taking Actos. Cipriano, 81, was diagnosed with bladder cancer in July 2012, 14 months after she began taking Actos. Triana, 80, was diagnosed in May 2012 after she had been taking Actos for roughly two years. Both women have undergone multiple surgeries to remove tumors within the last few years. The U.S. Food and Drug Administration (FDA) announced in 2011 that taking Actos for more than a year "may be associated with an increased risk of bladder cancer."
The Cipriano and Triana cases have been combined, and opening statements begin Monday. The trial is expected to take between eight and ten weeks. According to the Las Vegas Review Journal, Cipriano plans to seek a multibillion-dollar verdict.
Five More Actos Bladder Cancer Lawsuits Filed in Federal Court
February 3, 2014
The lawsuits claim that Takeda concealed clinical data linking Actos to bladder cancer, and failed to inform consumers, physicians, and the medical community about the dangers of the drug. According to the lawsuit, Takeda had known about a link between Actos and bladder cancer prior to the drug receiving approval from the U.S. Food and Drug Administration (FDA) in July of 1999. As a result of this deception, the plaintiffs allege that neither they nor their doctors knew, nor could they have known, about the risk of developing bladder cancer associated with the use of Actos.
A jury deciding a case against Takeda Pharmaceutical Co. will be allowed to hear claims that the drug maker intentionally destroyed files related to Actos (pioglitazone), a Type 2 diabetes drug. Takeda, the company that brought Actos to market in 1999, has been named in thousands of lawsuits claiming the drug causes bladder cancer.
According to Bloomberg, Takeda has admitted that they can't find Actos files that were "compiled by 46 current and former employees involved with the development, marketing and sale of Actos, including two directors." Some Actos related files were deleted from company computers after Takeda executives told employees to hold onto any Actos files. U.S. District Judge Rebecca Doherty said in her filing that "the breadth of Takeda leadership whose files have been lost, deleted or destroyed is, in and of itself, disturbing."
First Federal Actos Bladder Cancer Trial to Begin Next Month
January 16, 2014
The first Actos case to go before a jury in federal court is scheduled to begin opening arguments on February 3. The case involves a New York man who developed bladder cancer while taking Actos, a diabetes drug manufactured by Takeda Pharmaceutical.
Terrence Allen, who was on Actos for roughly seven years, was diagnosed with bladder cancer in January of 2011. According to the lawsuit, Allen claims that his bladder cancer was caused by taking Actos, and that Takeda failed to warn Actos users about the risks associated with the drug.